Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 113 articles: HTML format

Single Articles

November 2022
1. LIU Y, Shi J, Li L, Wu T, et al
   Spontaneous Mutational Patterns and Novel Mutations for Delamanid Resistance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2022 Nov 30:e0053122. doi: 10.1128/aac.00531.
   PubMed     Abstract available
   
   
   
2. WONG CF, Saw WG, Basak S, Sano M, et al
   Structural Elements Involved in ATP Hydrolysis Inhibition and ATP Synthesis of Tuberculosis and Nontuberculous Mycobacterial F-ATP Synthase Decipher New Targets for Inhibitors.
   Antimicrob Agents Chemother. 2022 Nov 29:e0105622. doi: 10.1128/aac.01056.
   PubMed     Abstract available
   
   
   
3. MANSJO M, Karlsson Lindsjo O, Gronfors Seeth C, Groenheit R, et al
   The ddn Trp20Stop Mutation and Its Association with Lineage 4.5 and Resistance to Delamanid and Pretomanid in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2022 Nov 21:e0102622. doi: 10.1128/aac.01026.
   PubMed     Abstract available
   
   
   
4. LYONS MA
   Pharmacodynamics and Bactericidal Activity of Combination Regimens in Pulmonary Tuberculosis: Application to Bedaquiline-Pretomanid-Pyrazinamide.
   Antimicrob Agents Chemother. 2022 Nov 15:e0089822. doi: 10.1128/aac.00898.
   PubMed     Abstract available
   
   
   
5. SARATHY JP, Zimmerman MD, Gengenbacher M, Dartois V, et al
   Mycobacterium tuberculosis DprE1 Inhibitor OPC-167832 Is Active against Mycobacterium abscessus In Vitro.
   Antimicrob Agents Chemother. 2022 Nov 9:e0123722. doi: 10.1128/aac.01237.
   PubMed     Abstract available
   
   
   
6. MON AS, Ei PW, Htwe MM, Nyunt MH, et al
   First Detection of Mycobacterium tuberculosis Clinical Isolates Harboring I491F Borderline Resistance rpoB Mutation in Myanmar.
   Antimicrob Agents Chemother. 2022 Nov 7:e0092522. doi: 10.1128/aac.00925.
   PubMed    
   
   
   
7. NGUYEN TQ, Hanh BTB, Jeon S, Heo BE, et al
   Synergistic Effect of Q203 Combined with PBTZ169 against Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2022 Nov 2:e0044822. doi: 10.1128/aac.00448.
   PubMed     Abstract available
   
   
   October 2022
8. AL-ZUBAIDI A, Cheung CY, Cook GM, Taiaroa G, et al
   RNase HI Depletion Strongly Potentiates Cell Killing by Rifampicin in Mycobacteria.
   Antimicrob Agents Chemother. 2022;66:e0209121.
   PubMed     Abstract available
   
   
   
9. PI R, Chen X, Meng J, Liu Q, et al
   Drug Degradation Caused by mce3R Mutations Confers Contezolid (MRX-I) Resistance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2022 Oct 3:e0103422. doi: 10.1128/aac.01034.
   PubMed     Abstract available
   
   
   September 2022
10. YAMADA W, Kim S, Almoslem M, Kim S, et al
    Combination Therapy to Kill Mycobacterium tuberculosis in Its Nonreplicating Persister Phenotype.
    Antimicrob Agents Chemother. 2022 Sep 27:e0069522. doi: 10.1128/aac.00695.
    PubMed     Abstract available
    
    
    
11. LIU F, Gao J, Gao M, Liu Y, et al
    Development and Validation of a Nomogram for Prediction of QT Interval Prolongation in Patients Administered Bedaquiline-Containing Regimens in China: a Modeling Study.
    Antimicrob Agents Chemother. 2022;66:e0203321.
    PubMed     Abstract available
    
    
    
12. ZOU J, Chen S, Rao W, Fu L, et al
    Population Pharmacokinetic Modeling of Bedaquiline among Multidrug-Resistant Pulmonary Tuberculosis Patients from China.
    Antimicrob Agents Chemother. 2022 Sep 15:e0081122. doi: 10.1128/aac.00811.
    PubMed     Abstract available
    
    
    
13. SUNDELL J, Bienvenu E, Birgersson S, Abelo A, et al
    Effects of Enzyme Induction and Polymorphism on the Pharmacokinetics of Isoniazid and Rifampin in Tuberculosis/HIV Patients.
    Antimicrob Agents Chemother. 2022 Sep 7:e0227721. doi: 10.1128/aac.02277.
    PubMed     Abstract available
    
    
    August 2022
14. KIM LH, Kang SM, Whang J, Kwon KW, et al
    Novel Antibacterial Activity of Febuxostat, an FDA-Approved Antigout Drug against Mycobacterium tuberculosis Infection.
    Antimicrob Agents Chemother. 2022 Aug 30:e0076222. doi: 10.1128/aac.00762.
    PubMed     Abstract available
    
    
    
15. SHEE S, Singh S, Tripathi A, Thakur C, et al
    Moxifloxacin-Mediated Killing of Mycobacterium tuberculosis Involves Respiratory Downshift, Reductive Stress, and Accumulation of Reactive Oxygen Species.
    Antimicrob Agents Chemother. 2022 Aug 17:e0059222. doi: 10.1128/aac.00592.
    PubMed     Abstract available
    
    
    
16. GEBERETSADIK G, Inaizumi A, Nishiyama A, Yamaguchi T, et al
    Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs.
    Antimicrob Agents Chemother. 2022 Aug 15:e0017122. doi: 10.1128/aac.00171.
    PubMed     Abstract available
    
    
    
17. BRUNAUGH AD, Walz A, Warnken Z, Pearce C, et al
    Respirable Clofazimine Particles Produced by Air Jet Milling Technique Are Efficacious in Treatment of BALB/c Mice with Chronic Mycobacterium tuberculosis Infection.
    Antimicrob Agents Chemother. 2022 Aug 9:e0018622. doi: 10.1128/aac.00186.
    PubMed     Abstract available
    
    
    
18. BARNIER JP, Saidjalolov S, Bouchet F, Mayer L, et al
    Modulation of the Specificity of Carbapenems and Diazabicyclooctanes for Selective Activity against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 9:e0235721. doi: 10.1128/aac.02357.
    PubMed     Abstract available
    
    
    
19. YUN HY, Chang MJ, Jung H, Chang V, et al
    Prothionamide Dose Optimization Using Population Pharmacokinetics for Multidrug-Resistant Tuberculosis Patients.
    Antimicrob Agents Chemother. 2022 Aug 8:e0189321. doi: 10.1128/aac.01893.
    PubMed     Abstract available
    
    
    
20. DING Y, Zhu H, Fu L, Zhang W, et al
    Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 4:e0065822. doi: 10.1128/aac.00658.
    PubMed     Abstract available
    
    
    
21. POULTON NC, Azadian ZA, DeJesus MA, Rock JM, et al
    Mutations in rv0678 Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 3:e0090422. doi: 10.1128/aac.00904.
    PubMed     Abstract available
    
    
    
22. GRACIAA DS, Kipiani M, Magee MJ, Mikiashvili L, et al
    Linezolid Exposure Is Associated with Cytopenias in Patients Treated for Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 Aug 2:e0040822. doi: 10.1128/aac.00408.
    PubMed     Abstract available
    
    
    July 2022
23. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
    Correction for Shelton et al., "Deletion of Rv2571c Confers Resistance to Arylamide Compounds in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2022 Jul 25:e0096222. doi: 10.1128/aac.00962.
    PubMed    
    
    
    
24. MTSHALI S, Jacobs BA
    A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
    Antimicrob Agents Chemother. 2022 Jul 19:e0027422. doi: 10.1128/aac.00274.
    PubMed     Abstract available
    
    
    
25. MEHTA K, Guo T, Wallis RS, van der Graaf PH, et al
    Quantitative Systems Pharmacology Modeling Framework of Autophagy in Tuberculosis: Application to Adjunctive Metformin Host-Directed Therapy.
    Antimicrob Agents Chemother. 2022 Jul 14:e0036622. doi: 10.1128/aac.00366.
    PubMed     Abstract available
    
    
    June 2022
26. RIVIERE E, Verboven L, Dippenaar A, Goossens S, et al
    Variants in Bedaquiline-Candidate-Resistance Genes: Prevalence in Bedaquiline-Naive Patients, Effect on MIC, and Association with Mycobacterium tuberculosis Lineage.
    Antimicrob Agents Chemother. 2022 Jun 27:e0032222. doi: 10.1128/aac.00322.
    PubMed     Abstract available
    
    
    
27. ABOLHASSANI-CHIMEH R, Akkerman OW, Saktiawati AMI, Punt NC, et al
    Population Pharmacokinetic Modelling and Limited Sampling Strategies for Therapeutic Drug Monitoring of Pyrazinamide in Patients with Tuberculosis.
    Antimicrob Agents Chemother. 2022 Jun 21:e0000322. doi: 10.1128/aac.00003.
    PubMed     Abstract available
    
    
    
28. WALTER K, Kokesch-Himmelreich J, Treu A, Waldow F, et al
    Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.
    Antimicrob Agents Chemother. 2022;66:e0158821.
    PubMed     Abstract available
    
    
    May 2022
29. NUERMBERGER EL, Martinez-Martinez MS, Sanz O, Urones B, et al
    GSK2556286 Is a Novel Antitubercular Drug Candidate Effective In Vivo with the Potential To Shorten Tuberculosis Treatment.
    Antimicrob Agents Chemother. 2022 May 24:e0013222. doi: 10.1128/aac.00132.
    PubMed     Abstract available
    
    
    
30. KAWUMA AN, Wasmann RE, Dooley KE, Boffito M, et al
    Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Antimicrob Agents Chemother. 2022 May 23:e0021522. doi: 10.1128/aac.00215.
    PubMed     Abstract available
    
    
    
31. PAUL A, Nair RR, Jakkala K, Pradhan A, et al
    Elevated Levels of Three Reactive Oxygen Species and Fe(II) in the Antibiotic-Surviving Population of Mycobacteria Facilitate De Novo Emergence of Genetic Resisters to Antibiotics.
    Antimicrob Agents Chemother. 2022;66:e0228521.
    PubMed     Abstract available
    
    
    
32. CONKLE-GUTIERREZ D, Kim C, Ramirez-Busby SM, Modlin SJ, et al
    Distribution of Common and Rare Genetic Markers of Second-Line-Injectable-Drug Resistance in Mycobacterium tuberculosis Revealed by a Genome-Wide Association Study.
    Antimicrob Agents Chemother. 2022 May 9:e0207521. doi: 10.1128/aac.02075.
    PubMed     Abstract available
    
    
    
33. VAN DER LAAN LE, Garcia-Prats AJ, Schaaf HS, Chirehwa M, et al
    Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2022 May 4:e0226421. doi: 10.1128/aac.02264.
    PubMed     Abstract available
    
    
    April 2022
34. RAGUNATHAN P, Dick T, Gruber G
    Anti-Mycobacterium abscessus Activity of Tuberculosis F-ATP Synthase Inhibitor GaMF1.
    Antimicrob Agents Chemother. 2022 Apr 28:e0001822. doi: 10.1128/aac.00018.
    PubMed     Abstract available
    
    
    
35. GARCIA-PRATS AJ, Frias M, van der Laan L, De Leon A, et al
    Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
    Antimicrob Agents Chemother. 2022 Apr 11:e0214421. doi: 10.1128/aac.02144.
    PubMed     Abstract available
    
    
    
36. CHAUHAN U, Barth VC, Woychik NA
    tRNA(fMet) Inactivating Mycobacterium tuberculosis VapBC Toxin-Antitoxin Systems as Therapeutic Targets.
    Antimicrob Agents Chemother. 2022 Apr 11:e0189621. doi: 10.1128/aac.01896.
    PubMed     Abstract available
    
    
    
37. ZHANG T, Yu X, Wen S, Xue Y, et al
    Bone Penetration of Cycloserine in Osteoarticular Tuberculosis Patients of China.
    Antimicrob Agents Chemother. 2022 Apr 11:e0222421. doi: 10.1128/aac.02224.
    PubMed     Abstract available
    
    
    March 2022
38. TASNEEN R, Garcia A, Converse PJ, Zimmerman MD, et al
    Novel Regimens of Bedaquiline-Pyrazinamide Combined with Moxifloxacin, Rifabutin, Delamanid and/or OPC-167832 in Murine Tuberculosis Models.
    Antimicrob Agents Chemother. 2022 Mar 22:e0239821. doi: 10.1128/aac.02398.
    PubMed     Abstract available
    
    
    
39. DIDE-AGOSSOU C, Bauman AA, Ramey ME, Rossmassler K, et al
    Combination of Mycobacterium tuberculosis RS Ratio and CFU Improves the Ability of Murine Efficacy Experiments to Distinguish between Drug Treatments.
    Antimicrob Agents Chemother. 2022 Mar 21:e0231021. doi: 10.1128/aac.02310.
    PubMed     Abstract available
    
    
    
40. BASARAB GS, Ghorpade S, Gibhard L, Mueller R, et al
    Spiropyrimidinetriones: a Class of DNA Gyrase Inhibitors with Activity against Mycobacterium tuberculosis and without Cross-Resistance to Fluoroquinolones.
    Antimicrob Agents Chemother. 2022 Mar 10:e0219221. doi: 10.1128/aac.02192.
    PubMed     Abstract available
    
    
    
41. SHELTON C, McNeil M, Allen R, Flint L, et al
    Triazolopyrimidines Target Aerobic Respiration in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2022 Mar 9:e0204121. doi: 10.1128/aac.02041.
    PubMed     Abstract available
    
    
    January 2022
42. BERG A, Clary J, Hanna D, Nuermberger E, et al
    Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database.
    Antimicrob Agents Chemother. 2022 Jan 31:AAC0179321. doi: 10.1128/AAC.01793.
    PubMed     Abstract available
    
    
    
43. DOMENECH P, Mouhoub E, Reed MB
    Experimental confirmation that an uncommon rrs gene mutation (g878a) of Mycobacterium tuberculosis confers resistance to streptomycin.
    Antimicrob Agents Chemother. 2022 Jan 24:AAC0191521. doi: 10.1128/AAC.01915.
    PubMed     Abstract available
    
    
    
44. KOELE SE, van Beek SW, Maartens G, Brust JCM, et al
    Optimized loading dose strategies for bedaquiline when restarting interrupted drug-resistant tuberculosis treatment.
    Antimicrob Agents Chemother. 2022 Jan 10:AAC0174921. doi: 10.1128/AAC.01749.
    PubMed     Abstract available
    
    
    December 2021
45. LYONS MA
    Pharmacodynamics and the Bactericidal Activity of Bedaquiline in Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0163621. doi: 10.1128/AAC.01636.
    PubMed     Abstract available
    
    
    
46. KIM JS, Kim YH, Lee SH, Kim YH, et al
    Early Bactericidal Activity of Delpazolid (LCB01-0371) in Patients with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0168421. doi: 10.1128/AAC.01684.
    PubMed     Abstract available
    
    
    
47. VERMA R, Gurumurthy M, Yeo BCM, Lu Q, et al
    Effects of increasing concentrations of rifampicin on different Mycobacterium tuberculosis lineages in a Whole blood Bactericidal Activity Assay.
    Antimicrob Agents Chemother. 2021 Dec 6:AAC0169921. doi: 10.1128/AAC.01699.
    PubMed     Abstract available
    
    
    November 2021
48. SASAKI T, Svensson EM, Wang X, Wang Y, et al
    Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 29:AAC0160821. doi: 10.1128/AAC.01608.
    PubMed     Abstract available
    
    
    
49. VOGENSEN VB, Bolhuis MS, Sturkenboom MGG, van der Werf TS, et al
    Clinical relevance of rifampicin-moxifloxacin interaction in isoniazid resistant/intolerant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Nov 22:AAC0182921. doi: 10.1128/AAC.01829.
    PubMed     Abstract available
    
    
    
50. YU JF, Xu JT, Yang SS, Gao MN, et al
    Decreased methylenetetrahydrofolate reductase activity leads to increased sensitivity to para-aminosalicylic acid in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Nov 15:AAC0146521. doi: 10.1128/AAC.01465.
    PubMed     Abstract available
    
    
    October 2021
51. GANAPATHY US, Del Rio RG, Cacho-Izquierdo M, Ortega F, et al
    A Mycobacterium tuberculosis NBTI DNA gyrase inhibitor is active against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0151421. doi: 10.1128/AAC.01514.
    PubMed     Abstract available
    
    
    
52. RADTKE KK, Ernest JP, Zhang N, Ammerman NC, et al
    Comparative efficacy of rifapentine alone and in combination with isoniazid for latent tuberculosis infection: a translational pharmacokinetic-pharmacodynamic modelling study.
    Antimicrob Agents Chemother. 2021 Oct 4:AAC0170521. doi: 10.1128/AAC.01705.
    PubMed     Abstract available
    
    
    September 2021
53. ALMEIDA D, Converse PJ, Li SY, Upton AM, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 27:AAC0141221. doi: 10.1128/AAC.01412.
    PubMed     Abstract available
    
    
    
54. ABDELWAHAB MT, Wasserman S, Brust JCM, Dheda K, et al
    Linezolid population pharmacokinetics in South African adults with drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2021 Sep 20:AAC0138121. doi: 10.1128/AAC.01381.
    PubMed     Abstract available
    
    
    August 2021
55. SALAAM-DREYER Z, Streicher EM, Sirgel FA, Menardo F, et al
    Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0036421. doi: 10.1128/AAC.00364.
    PubMed     Abstract available
    
    
    
56. VARGAS R JR, Freschi L, Spitaleri A, Tahseen S, et al
    The role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex.
    Antimicrob Agents Chemother. 2021 Aug 30:AAC0116421. doi: 10.1128/AAC.01164.
    PubMed     Abstract available
    
    
    
57. RAI D, Mehra S
    The mycobacterial efflux pump EfpA can induce high drug tolerance to many anti-tuberculosis drugs, including moxifloxacin, in Mycobacterium smegmatis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0026221. doi: 10.1128/AAC.00262.
    PubMed     Abstract available
    
    
    
58. WAGH S, Rathi C, Lukka PB, Parmar K, et al
    Model-Based Exposure-Response Assessment for Spectinamide 1810 in a Mouse Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 23:AAC0174420. doi: 10.1128/AAC.01744.
    PubMed     Abstract available
    
    
    
59. GUO S, Wang B, Fu L, Chen X, et al
    In vitro and in vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Aug 16:AAC0097421. doi: 10.1128/AAC.00974.
    PubMed     Abstract available
    
    
    
60. ROBERTSON GT, Ramey ME, Massoudi LM, Carter CL, et al
    Comparative Analysis of Pharmacodynamics in the C3HeB/FeJ Mouse Tuberculosis Model for DprE1 inhibitors TBA-7371, PBTZ169 and OPC-167832.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0058321. doi: 10.1128/AAC.00583.
    PubMed     Abstract available
    
    
    
61. NGWALERO P, Brust JCM, van Beek SW, Wasserman S, et al
    Relationship between plasma and intracellular concentrations of bedaquiline and its M2 metabolite in South African patients with rifampin-resistant TB.
    Antimicrob Agents Chemother. 2021 Aug 9:AAC0239920. doi: 10.1128/AAC.02399.
    PubMed     Abstract available
    
    
    
62. KIM S, Yamada WM, Duncanson B, Nole J, et al
    Building optimal 3-drug combination chemotherapy regimens to eradicate Mycobacterium tuberculosis in its slow growth acid phase.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0069321. doi: 10.1128/AAC.00693.
    PubMed     Abstract available
    
    
    
63. CUMMING BM, Baig Z, Addicott KW, Chen D, et al
    Host bioenergetic parameters reveal cytotoxicity of anti-tuberculosis drugs undetected using conventional viability assays.
    Antimicrob Agents Chemother. 2021 Aug 2:AAC0093221. doi: 10.1128/AAC.00932.
    PubMed     Abstract available
    
    
    July 2021
64. CHIREHWA MT, Court R, de Kock M, Wiesner L, et al
    The effect of isoniazid intake on ethionamide pharmacokinetics and target attainment in multidrug-resistant tuberculosis patients.
    Antimicrob Agents Chemother. 2021 Jul 26:AAC0027821. doi: 10.1128/AAC.00278.
    PubMed     Abstract available
    
    
    
65. YU W, Buhari Y, Wang S, Tian X, et al
    Sterilizing Effects of Novel Regimens Containing TB47, Clofazimine and Linezolid in a Murine Model of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0070621. doi: 10.1128/AAC.00706.
    PubMed     Abstract available
    
    
    
66. VAN SCHIE L, Borgers K, Michielsen G, Plets E, et al
    Exploration of synergistic action of cell wall-degrading enzymes against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 19:AAC0065921. doi: 10.1128/AAC.00659.
    PubMed     Abstract available
    
    
    
67. ERNEST JP, Sarathy J, Wang N, Kaya F, et al
    Lesion penetration and activity limit the utility of second-line injectable agents in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0050621. doi: 10.1128/AAC.00506.
    PubMed     Abstract available
    
    
    
68. GEWITZ AD, Solans BP, Mac Kenzie WR, Heilig C, et al
    A Longitudinal Model-Based Biomarker Analysis of Exposure Response in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jul 12:AAC0179420. doi: 10.1128/AAC.01794.
    PubMed     Abstract available
    
    
    
69. EGBELOWO O, Sarathy JP, Gausi K, Zimmerman MD, et al
    Pharmacokinetics and target attainment of SQ109 in plasma and human-like tuberculosis lesions in rabbits.
    Antimicrob Agents Chemother. 2021 Jul 6:AAC0002421. doi: 10.1128/AAC.00024.
    PubMed     Abstract available
    
    
    June 2021
70. WERNGREN J, Mansjo M, Glader M, Hoffner S, et al
    Detection of pyrazinamide heteroresistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 28:AAC0072021. doi: 10.1128/AAC.00720.
    PubMed     Abstract available
    
    
    
71. ZENG S, Zhang J, Sun M, Zhang X, et al
    Nitric oxide-dependent electron transport chain inhibition by the cytochrome bc1 inhibitor and pretomanid combination kills Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 21:AAC0095621. doi: 10.1128/AAC.00956.
    PubMed     Abstract available
    
    
    
72. SHETYE GS, Choi KB, Kim CY, Franzblau SG, et al
    In Vitro Profiling of Anti-tubercular Compounds by Rapid, Efficient, and Non-Destructive Assays Using Auto-luminescent Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0028221. doi: 10.1128/AAC.00282.
    PubMed     Abstract available
    
    
    
73. SHIBATA M, Masuda M, Sasahara K, Sasabe H, et al
    Prediction of Human Pharmacokinetic Profiles of the Anti-tuberculosis Drug Delamanid from Nonclinical Data: Potential Therapeutic Value Against Extrapulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2021 Jun 7:AAC0257120. doi: 10.1128/AAC.02571.
    PubMed     Abstract available
    
    
    
74. ZAINABADI K, Walsh KF, Vilbrun SC, Mathurin LD, et al
    Characterization of differentially detectable Mycobacterium tuberculosis in the sputum of subjects with drug sensitive or drug resistant tuberculosis before and after two months of therapy.
    Antimicrob Agents Chemother. 2021 Jun 1:AAC0060821. doi: 10.1128/AAC.00608.
    PubMed     Abstract available
    
    
    May 2021
75. JOHANSEN MD, Shalini, Kumar S, Raynaud C, et al
    Biological and biochemical evaluation of isatin-isoniazid hybrids as bactericidal candidates against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00011.
    PubMed     Abstract available
    
    
    
76. MOK S, Roycroft E, Flanagan PR, Montgomery L, et al
    Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis isolates.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.02617.
    PubMed     Abstract available
    
    
    
77. WASSERMAN S, Davis A, Stek C, Chirehwa M, et al
    Plasma pharmacokinetics of high dose oral versus intravenous rifampicin in patients with tuberculous meningitis: a randomized controlled trial.
    Antimicrob Agents Chemother. 2021 May 10. pii: AAC.00140.
    PubMed     Abstract available
    
    
    April 2021
78. SONNENKALB L, Strohe G, Dreyer V, Andres S, et al
    Microevolution of Mycobacterium tuberculosis hetero-resistance subpopulations in a patient receiving 27 years of tuberculosis treatment in Germany.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02520.
    PubMed     Abstract available
    
    
    
79. TASNEEN R, Mortensen DS, Converse PJ, Urbanowski ME, et al
    Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.00253.
    PubMed     Abstract available
    
    
    
80. LEY SD, Pillay S, Streicher EM, van der Heijden YF, et al
    Melting the Eis: non-detection of kanamycin resistance markers by routine diagnostic tests and identification of new eis-promoter variants.
    Antimicrob Agents Chemother. 2021 Apr 26. pii: AAC.02502.
    PubMed     Abstract available
    
    
    
81. ABDELWAHAB MT, Court R, Everitt D, Diacon AH, et al
    The effect of Clofazimine Concentration on QT prolongation in patients treated for tuberculosis.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.02687.
    PubMed     Abstract available
    
    
    
82. SUNDELL J, Wijk M, Bienvenu E, Abelo A, et al
    Factors affecting the pharmacokinetics of pyrazinamide and its metabolites in patients co-infected with HIV - implications for individualized dosing.
    Antimicrob Agents Chemother. 2021 Apr 19. pii: AAC.00046.
    PubMed     Abstract available
    
    
    
83. LIN WH, Lee WT, Tsai HY, Jou R, et al
    Disputed rpoB mutations in Mycobacterium tuberculosis and tuberculosis treatment outcomes.
    Antimicrob Agents Chemother. 2021 Apr 12. pii: AAC.01573.
    PubMed     Abstract available
    
    
    March 2021
84. ARDIZZONI E, Ariza E, Mulengwa D, Mpala Q, et al
    Thin layer agar-based direct phenotypic drug-susceptibility testing on sputum in Eswatini rapidly detects Mycobacterium tuberculosis growth and rifampicin resistance, otherwise missed by WHO endorsed diagnostic tests.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.02263.
    PubMed     Abstract available
    
    
    
85. MODLIN SJ, Marbach T, Werngren J, Mansjo M, et al
    Atypical Genetic Basis of Pyrazinamide Resistance in Mono-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Mar 15. pii: AAC.01916.
    PubMed     Abstract available
    
    
    February 2021
86. OMOLLO C, Singh V, Kigondu E, Wasuna A, et al
    Developing synergistic drug combinations to restore antibiotic sensitivity in drug-resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02554.
    PubMed     Abstract available
    
    
    
87. SHELTON CD, McNeil MB, Early JV, Ioerger TR, et al
    Deletion of Rv2571c confers resistance to arylamide compounds in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.02334.
    PubMed     Abstract available
    
    
    
88. VILCHEZE C, Jacobs WR Jr
    The promises and limitations of N-acetylcysteine as a potentiator of first-line and second-line tuberculosis drugs.
    Antimicrob Agents Chemother. 2021 Feb 22. pii: AAC.01703.
    PubMed     Abstract available
    
    
    
89. LUN S, Xiao S, Zhang W, Wang S, et al
    Therapeutic potential of coumestan Pks13 inhibitors for tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02190.
    PubMed     Abstract available
    
    
    
90. PIETERMAN ED, van den Berg S, van der Meijden A, Svensson EM, et al
    Higher dosing of rifamycins does not increase activity against M. tuberculosis in the hollow fibre infection model.
    Antimicrob Agents Chemother. 2021 Feb 8. pii: AAC.02255.
    PubMed     Abstract available
    
    
    
91. XU J, Converse PJ, Upton AM, Mdluli K, et al
    Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2021 Feb 1. pii: AAC.02418.
    PubMed     Abstract available
    
    
    January 2021
92. HO VQT, Verboom T, Rong MK, Habjan E, et al
    Heterologous expression of ethA and katG in Mycobacterium marinum enables the rapid identification of new prodrugs active against Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2021 Jan 25. pii: AAC.01445.
    PubMed     Abstract available
    
    
    
93. DRUSANO GL, Kim S, Almoslem M, Schmidt S, et al
    The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
    Antimicrob Agents Chemother. 2021;65.
    PubMed     Abstract available
    
    
    
94. KHAN MZ, Nandicoori VK
    Deletion of PknG abates reactivation of latent Mycobacterium tuberculosis in mice.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02095.
    PubMed     Abstract available
    
    
    
95. DRUSANO GL, Rogers S, Brown D, Peloquin CA, et al
    Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
    Antimicrob Agents Chemother. 2021 Jan 19. pii: AAC.02533.
    PubMed     Abstract available
    
    
    
96. ZHU H, Fu L, Wang B, Chen X, et al
    Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis, in different administration intervals in mouse tuberculosis models.
    Antimicrob Agents Chemother. 2021 Jan 11. pii: AAC.02164.
    PubMed     Abstract available
    
    
    December 2020
97. VALAFAR SJ
    A Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02091.
    PubMed     Abstract available
    
    
    
98. LIN SY, Feng JY, Lee CY, Lin YC, et al
    Completion and adverse drug events of latent tuberculosis infection treatment in patients receiving dialysis: predictors and impacts of different regimens in a prospective cohort study.
    Antimicrob Agents Chemother. 2020 Dec 23. pii: AAC.02184.
    PubMed     Abstract available
    
    
    November 2020
99. VIJAY S, Nhung HN, Bao NLH, Thu DDA, et al
    Most-probable number based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical M. tuberculosis isolates.
    Antimicrob Agents Chemother. 2020 Nov 30. pii: AAC.01439.
    PubMed     Abstract available
    
    
    
100. IGNATIUS EH, Abdelwahab MT, Hendricks B, Gupte N, et al
     Pretomanid Pharmacokinetics in the Presence of Rifamycins: interim Results from a Randomized Trial among Patients with Tuberculosis.
     Antimicrob Agents Chemother. 2020 Nov 23. pii: AAC.01196.
     PubMed     Abstract available
     
     
     
101. PANJASAWATWONG N, Wattanakul T, Hoglund RM, Bang ND, et al
     Population pharmacokinetic properties of anti-tuberculosis drugs in Vietnamese children with tuberculous meningitis.
     Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.00487.
     PubMed     Abstract available
     
     
     
102. GRZEGORZEWICZ AE, Lelievre J, Esquivias J, Angala B, et al
     Lack of Specificity of Phenotypic Screens for Inhibitors of the Mycobacterium tuberculosis FAS-II System.
     Antimicrob Agents Chemother. 2020 Nov 2. pii: AAC.01914.
     PubMed     Abstract available
     
     
     October 2020
103. ARUN KB, Madhavan A, Abraham B, Balaji M, et al
     Acetylation of isoniazid - a novel mechanism of isoniazid resistance in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.00456.
     PubMed     Abstract available
     
     
     
104. WILLBY M, Chopra P, Lemmer D, Klein K, et al
     Molecular evaluation of fluoroquinolone resistance in serial Mycobacterium tuberculosis isolates from individuals diagnosed with multidrug-resistant tuberculosis.
     Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01663.
     PubMed     Abstract available
     
     
     
105. MALLIKAARJUN S, Chapagain ML, Sasaki T, Hariguchi N, et al
     Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Pulmonary Multidrug-Resistant Tuberculosis Patients.
     Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01207.
     PubMed     Abstract available
     
     
     
106. WANG X, Mallikaarjun S, Gibiansky E
     Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multi-Drug Resistant Tuberculosis.
     Antimicrob Agents Chemother. 2020 Oct 26. pii: AAC.01202.
     PubMed     Abstract available
     
     
     
107. RIFAT D, Li SY, Ioerger T, Shah K, et al
     Mutations in fbiD (Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis.
     Antimicrob Agents Chemother. 2020 Oct 19. pii: AAC.01948.
     PubMed     Abstract available
     
     
     
108. SATHKUMARA HD, Hansen K, Miranda-Hernandez S, Govan B, et al
     Disparate effects of metformin on Mycobacterium tuberculosis infection in diabetic and non-diabetic mice.
     Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.01422.
     PubMed     Abstract available
     
     
     
109. VAN DER WALT ML, Shean K, Becker P, Keddy KH, et al
     Treatment outcomes and adverse drug effects of ethambutol, cycloserine and terizidone for treatment of multi-drug resistant tuberculosis in South Africa.
     Antimicrob Agents Chemother. 2020 Oct 12. pii: AAC.00744.
     PubMed     Abstract available
     
     
     April 2020
110. FARAJ A, Svensson RJ, Diacon AH, Simonsson USH, et al
     Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients.
     Antimicrob Agents Chemother. 2020;64.
     PubMed     Abstract available
     
     
     
111. HAYASHI M, Nishiyama A, Kitamoto R, Tateishi Y, et al
     Adduct Formation of Delamanid with NAD in Mycobacteria.
     Antimicrob Agents Chemother. 2020;64.
     PubMed     Abstract available
     
     
     January 2020
112. REINGEWERTZ TH, Meyer T, McIntosh F, Sullivan J, et al
     Differential Sensitivity of Mycobacteria to Isoniazid Is Related to Differences in KatG-Mediated Enzymatic Activation of the Drug.
     Antimicrob Agents Chemother. 2020;64.
     PubMed     Abstract available
     
     
     
113. WASSERMAN S, Huo S, Ky K, Malig YN, et al
     CORRELATION OF LINEZOLID HAIR CONCENTRATIONS WITH PLASMA EXPOSURE IN PATIENTS WITH DRUG-RESISTANT TB.
     Antimicrob Agents Chemother. 2020 Jan 13. pii: AAC.02145.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Tuberculosis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: